Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000153556 | SCV000203086 | uncertain significance | not provided | 2014-04-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001850100 | SCV002167429 | likely benign | Nemaline myopathy 2 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004649073 | SCV005146299 | uncertain significance | Inborn genetic diseases | 2024-05-14 | criteria provided, single submitter | clinical testing | The c.218G>A (p.R73Q) alteration is located in exon 5 (coding exon 3) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 218, causing the arginine (R) at amino acid position 73 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |